{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:45:50Z","timestamp":1787323550328,"version":"build-2736575974"},"reference-count":10,"publisher":"Termedia Sp. z.o.o.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"DOI":"10.5114\/aoms\/230992","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:08:41Z","timestamp":1787321321000},"source":"Crossref","is-referenced-by-count":0,"title":["Teclistamab for ultrahigh-risk multiple myeloma with isolated central nervous system relapse"],"prefix":"10.5114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0239-8043","authenticated-orcid":true,"given":"Huan","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Hematology, Army Medical Center of PLA, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8067-0035","authenticated-orcid":true,"given":"Ran","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Army Medical Center of PLA, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-7593","authenticated-orcid":false,"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Army Medical Center of PLA, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref-1966794","doi-asserted-by":"crossref","unstructured":"Blad\u00e9 J, Beksac M, Caers J, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J 2022; 12: 45.","DOI":"10.1038\/s41408-022-00643-3"},{"key":"ref-1966795","doi-asserted-by":"crossref","unstructured":"Jurczyszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol 2016; 91: 575-80.","DOI":"10.1002\/ajh.24351"},{"key":"ref-1966796","doi-asserted-by":"crossref","unstructured":"Egan PA, Elder PT, Deighan WI, et al. Multiple myeloma with central nervous system relapse. Haematologica 2020; 105: 1780-90.","DOI":"10.3324\/haematol.2020.248518"},{"key":"ref-1966797","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2022; 387: 495-505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"ref-1966798","doi-asserted-by":"crossref","unstructured":"Landry I, Binder AF, Yorker M, Ramirez S. Redefining central nervous system multiple myeloma: from rare phenomenon to emerging entity. Blood Rev 2025; 74: 101343.","DOI":"10.1016\/j.blre.2025.101343"},{"key":"ref-1966799","doi-asserted-by":"crossref","unstructured":"Zheng YH, Shen HY, Chen X, et al. Prognostic model and immune-infiltrating cell landscape based on differentially expressed autophagy-related genes in TP53-mutated multiple myeloma. Arch Med Sci 2021; 20: 1619-30.","DOI":"10.5114\/aoms\/140293"},{"key":"ref-1966800","doi-asserted-by":"crossref","unstructured":"Katodritou E, Terpos E. Central nervous system myeloma: pathogenesis, diagnostic challenges, and practical management strategies. Hemasphere 2025; 9: e70213.","DOI":"10.1002\/hem3.70213"},{"key":"ref-1966801","doi-asserted-by":"crossref","unstructured":"Wang Y, Zu C, Teng X, et al. BCMA CAR-T therapy is safe and effective for refractory\/relapsed multiple myeloma with central nervous system involvement. J Immunother 2022; 45: 25-34.","DOI":"10.1097\/CJI.0000000000000391"},{"key":"ref-1966802","doi-asserted-by":"crossref","unstructured":"Mutlu YG, Kaya SY, Maral S, et al. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. Front Immunol 2023; 14: 1276295.","DOI":"10.3389\/fimmu.2023.1276295"},{"key":"ref-1966803","doi-asserted-by":"crossref","unstructured":"Noveihed A, Al Hadidi S, Mohan M, Shah MR. Bispecific antibody therapy in CNS myeloma: early evidence from a multicentre cohort. Br J Haematol 2025; 207: 2161-6.","DOI":"10.1111\/bjh.70108"}],"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-230992-143595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-230992-143595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:08:46Z","timestamp":1787321326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Teclistamab-for-ultrahigh-risk-multiple-myeloma-with-isolated-central-nervous-system,230992,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":10,"alternative-id":["230992"],"URL":"https:\/\/doi.org\/10.5114\/aoms\/230992","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}